Printer Friendly

Ablynx completes patient recruitment in Phase IIb RESPIRE study of ALX-0171.

M2 EQUITYBITES-April 30, 2018-Ablynx completes patient recruitment in Phase IIb RESPIRE study of ALX-0171

(C)2018 M2 COMMUNICATIONS http://www.m2.com

Ablynx NV (EBR: ABLX) has successfully completed patient recruitment in its Phase IIb RESPIRE dose-ranging efficacy study of its novel inhaled drug candidate ALX-0171 to treat respiratory syncytial virus (RSV) infections, the company disclosed on Monday.

In total, the study has enrolled 180 infants (aged 1-24 months) who have been diagnosed with RSV and hospitalised for a lower respiratory tract infection.

The study will include a sequential dose escalation part, which has enrolled 36 infants. This will be followed by a parallel part, in which 144 infants will be randomly assigned to one of three dose groups of inhaled ALX-0171 or placebo. The drug will be administered once daily for three consecutive days.

ALX-0171 is a wholly-owned trivalent nanobody that binds to the F-protein of RSV in order to inhibit viral replication and neutralise RSV activity by blocking virus uptake into cells.

Data from the Phase IIb study is expected in the second half of 2018.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Apr 30, 2018
Words:189
Previous Article:SKF settles legal dispute with Peugeot and group companies.
Next Article:Curetis announces changes to its supervisory board.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters